A Study to Assess Brillouin Hydration Mapping for the Evaluation of Ocular Tissues and Diseases
Massachusetts General Hospital · with Massachusetts Eye and Ear Infirmary, National Eye Institute (NEI) · NCT07780890
Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.
Key facts
- Compensation
- Not posted. Ask the study team before screening.
- Who can join
- Ages 20–79 · All sexes
- Healthy volunteers
- Accepted
- Study type
- Observational
- Target enrollment
- 90
- US sites recruiting
- 1
- Study start
- August 18, 2026
- Record last updated
- August 25, 2026
Status re-checked against ClinicalTrials.gov within the last 12 hours.
What the study is about
The overall goal of this study is to develop Brillouin microscope as a novel tool for measuring biomechanical and hydration properties of human tissues in vivo.
Conditions: Fuchs Endothelial Corneal Dysfunction; Open Angle Glaucoma (OAG); Dry Eye Disease (DED); Keratoconus; Lasik Eye Surgery
Eligibility criteria
Copied from the official record. The study team makes the final decision at screening.
Show full criteria
Inclusion Criteria
- Healthy volunteers with normal eyes
- Visual acuity between +2 to -6 diopters
Exclusion Criteria
- History of refractive or cataract surgery
- History of ocular disease
- Active non-ophthalmic systemic disease
Recruiting US locations
Massachusetts General Brigham
Boston, MA 02114
Site contact: Soyeon (Selina) Ahn, PhD · 3396009736 · sahn14@mgh.harvard.edu
Study contacts (from the official record)
- Soyeon (Selina) Ahn, PhD · 3396009736 · sahn14@mgh.harvard.edu
- Seok-Hyun Yun, PhD · 6177688704 · syun@mgh.harvard.edu
Similar studies in Massachusetts
All healthy volunteers studies in Massachusetts →- RecruitingHealthy volunteersPhase 1/Phase 2
A Phase I/II Study of ITU512 in Healthy Participants and Patients With Sickle Cell Disease
Novartis Pharmaceuticals
- Location
- Boston, MA + 7 other US sites
- Eligibility basics
- Ages 12–55
- RecruitingHealthy volunteersPhase 1
Study to Evaluate the Safety, Pharmacokinetic, and Pharmacodynamic Effects of MY006 in Healthy Volunteers and Patients With Peanut Allergy
Mabylon AG
- Location
- Boston, MA + 7 other US sites
- Eligibility basics
- Ages 12–55
- RecruitingHealthy volunteersPhase 1
Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of HTX-001
Haya Therapeutics, Inc.
- Location
- Boston, MA + 1 other US site
- Eligibility basics
- Ages 18–70
- RecruitingHealthy volunteersPhase 1/Phase 2
Phase 1/2 Study of Respiratory Syncytial Virus and Human Metapneumovirus (RSV+HMPV) Vaccine Candidate in Adults 60 Years of Age and Older
Sanofi
- Location
- Boston, MA + 49 other US sites
- Eligibility basics
- Ages 60+